BioSpace News Archive

Alzheon, Inc. announced the appointment of Adem Albayrak as Head of Operations, and Earvin Liang, PhD, as Vice President of Clinical Development.

Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today announced its participation in the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021.

AbbVie (NYSE: ABBV) and REGENXBIO Inc. (Nasdaq: RGNX) today announced a partnership to develop and commercialize RGX-314, a potential one-time gene therapy for the treatment of wet age-related macular degeneration (wet AMD), diabetic retinopathy (DR) and other chronic retinal diseases.

Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the “Company”), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that Company CEO Dwight Egan will participate in a panel discussion hosted by Scott Gottlieb, M.D., titled “How We Can Defeat the Next Pandemic” at the H.C. Wainwright & Co. 2021 Global Investor Conference.

Trane Technologies (NYSE: TT), a global climate innovator, announced that it has signed an agreement to acquire Farrar Scientific, a leader in ultra-low temperature control for biopharmaceutical and other life science applications.

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced the submission of a Marketing Authorization Application (MAA) for the treatment of cholestatic liver disease in patients with Alagille syndrome (ALGS) to the European Medicines Agency (EMA).

Todos Medical, Ltd. today announced that its President & CEO Gerald Commissiong will be presenting at the H.C. Wainwright Annual Global Investment Conference being held virtually September 13-15, 2021.

SQZ Biotechnologies today announced that the first clinical translation of the company’s Tolerizing Antigen Carrier (TAC) platform in autoimmune diseases will be for celiac disease, a chronic autoimmune disorder that afflicts millions of patients and has no approved drug treatment.

Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), today announced that the first patient has been dosed in the Phase 1/2 trial of ZN-c3, the Company’s oral WEE1 inhibitor product candidate, in combination with gemcitabine, a chemotherapy used to treat certain malignant tumors, in pediatric and adult patients with relapsed or refractory osteosarcoma.

Adaptimmune Therapeutics plc (Nasdaq: ADAP), a leader in cell therapy to treat cancer, announced updated data from its Phase 1 SURPASS trial in multiple solid tumors to be presented in a digital poster at the upcoming European Society for Medical Oncology (ESMO) annual meeting.